Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Revance Therapeutics (NQ: RVNC )

26.26 USD +0.91 (+3.59%)
Official Closing Price Updated: 4:22 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Revance Therapeutics

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Revance to Participate in Upcoming Virtual Healthcare Conferences
Revance to Participate in Upcoming Virtual Healthcare Conferences 
From Business Wire News Releases
Worldwide Facial Injectable Industry to 2025 - by Type, Generation, End-user and Geography
From GlobeNewswire News Releases
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
From Business Wire News Releases
Ambrx Appoints Audit Executive Chris Nolet to Board of Directors
Ambrx Appoints Audit Executive Chris Nolet to Board of Directors 
From Business Wire News Releases
The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags BLUE Pre/Market Outlook NK
From Benzinga
Revance Therapeutics' DaxibotulinumtoxinA For Injection Improves Muscle Tone In Mid-Stage Upper Limb Spasticity
Revance Therapeutics Inc(NASDAQ:RVNC) hasreported topline datafromJUNIPER Phase 2 studyevaluating ... 
Tags News General RVNC
From Benzinga
Recap: Revance Therapeutics Q4 Earnings
Shares of Revance Therapeutics (NASDAQ:RVNC) increasedin after-market trading after the company reported Q4 results. Quarterly ... 
Tags Earnings RVNC Benzinga
From Benzinga
Revance Reports Fourth Quarter and Full Year 2020 Financial Results
Revance Reports Fourth Quarter and Full Year 2020 Financial Results 
From Business Wire News Releases
Revance Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity
Revance Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of ULS 
From Business Wire News Releases
Revance Appoints Biotech and Pharmaceutical Executive, Olivia C. Ware, and Fintech and Payments Thought Leader and Entrepreneur, Carey O’Connor Kolaja, to its Board of Directors
Revance Appoints Olivia C. Ware and Carey O’Connor Kolaja to Board of Directors 
From Business Wire News Releases
Analysts See 18% Upside For IHE
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Earnings Scheduled For February 22, 2021
Companies Reporting Before The Bell • Cooper Tire & Rubber (NYSE:CTB) is projected to report quarterly earnings at ... 
Tags PLOW RVNC GFL
From Benzinga
The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings
Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before ... 
Tags TBPH LNTH CTMX
From Benzinga
Revance Therapeutics's Earnings Outlook
On Monday, February 22, Revance Therapeutics (NASDAQ:RVNC) will release its latest earnings report. Benzinga's outlook for Revance ... 
Tags Market News RVNC Earnings
From Benzinga
Revance to Release Fourth Quarter and Full Year 2020 Financial Results on Monday, February 22, 2021
Revance to Release Fourth Quarter and Full Year 2020 Financial Results on Monday, February 22, 2021 
From Business Wire News Releases
Revance to Highlight Aesthetic Clinical Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Filler Study Results at Maui Derm for Dermatologists 2021
Revance to Highlight Aesthetic Clinical Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Filler Study Results at Maui Derm 
From Business Wire News Releases
Revance Issues Inaugural Environmental, Social and Governance (ESG) Report
Revance Issues Inaugural Environmental, Social and Governance (ESG) Report 
From Business Wire News Releases
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
From Business Wire News Releases
Revance to Participate in the 39th Annual J.P. Morgan Healthcare Conference
Revance to Participate in the 39th Annual J.P. Morgan Healthcare Conference 
From Business Wire News Releases
Revance Provides Corporate Update and Anticipated Milestones for 2021
Revance Provides Corporate Update and Anticipated Milestones for 2021 
From Business Wire News Releases
Revance Therapeutics Shows Improved Relative Strength; Still Shy Of Benchmark
Revance Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating 
From Investor's Business Daily
Stocks Showing Improved Relative Strength: Revance Therapeutics
A Relative Strength Rating upgrade for Revance Therapeutics shows improving technical performance. Will it continue? 
From Investor's Business Daily
Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injection
Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, and Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology... 
From PR Newswire
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
From Business Wire News Releases
Stocks Generating Improved Relative Strength: Revance Therapeutics
Revance Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating 
From Investor's Business Daily
Revance Reports Positive Efficacy and Duration Results from Phase 2 Upper Facial Lines Study
Revance Reports Positive Efficacy and Duration Results from Phase 2 Upper Facial Lines Study 
From Business Wire News Releases
Governor Lee, Commissioner Rolfe Announce Revance Therapeutics to Relocate Global Headquarters to Nashville
Governor Lee, Commissioner Rolfe Announce Revance Therapeutics to Relocate Global Headquarters to Nashville 
From Business Wire News Releases
Revance Therapeutics Shows Improved Relative Price Performance; Still Shy Of Benchmark
Revance Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
From Investor's Business Daily
The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions
Biotech stocks had a rather uneventful week, as the sector was seen mostly flatlining amid light trading volume ahead of the Thanksgiving holiday. The week kickstarted with lukewarm news on the... 
Tags Pharma/Biotech Stocks / Equities
From Blogs - TalkMarkets
The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions
Biotech stocks had a rather uneventful week, as the sector was seen mostly flatlining amid light trading volume ahead of the ... 
Tags YMAB LQDA BCRX
From Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account